Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment

Who May Qualify: - Patients aged 18 and older with moderate to severe orbitopathy; - Patients followed in endocrinology with the goal of achieving euthyroidism; - Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS); - Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy; - Patients with a CAS ≥ 3 or CAS \<3 with moderate to severe orbitopathy (according to EUGOGO); - Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment; - Patients who are not opposed to the reuse of their health data. Who Should NOT Join This Trial: - Patients who have undergone bone or fat decompression surgery; - Patients with severe corneal involvement (Grade B or C; NO SPECS classification); - Patients with optic neuropathy (Grade B and C; NO SPECS classification); - Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy; - Patients who have opposed the reuse of their health data. Always talk to your doctor about whether this trial is right for you.